Clin2
NCT06259292Likely a fitRecruiting

HHT patient registry tracking long-term outcomes

Hereditary Hemorrhagic TelangiectasiaArteriovenous MalformationsTelangiectasiaEpistaxisGastroIntestinal BleedingCerebral Arteriovenous MalformationsVascular Malformation

Part of Blood & lymphatic, Brain & nervous system, Digestive system, Ear, nose & throat, Genetic & congenital, Heart & circulation, Lungs & breathing clinical trials.

This registry collects health information from people with HHT over time to better understand the disease and improve care. Joining does not involve any experimental treatment, but your data will help researchers learn more about HHT.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
10,000 people
Ages
Any age
Study type
Observational

Who can take part

  • You must have been diagnosed with HHT, either by a doctor using the Curacao criteria or through a genetic test.
  • You must be able to give permission to join (or have a parent or legal representative do it for you).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07101575Not yet recruiting
Heart checkup for people with HHT

This study uses an echocardiogram (a heart ultrasound) to look for possible heart problems in people with hereditary hemorrhagic telangiectasia (HHT). It will help doctors understand how HHT affects the heart.

NCT06261333Enrolling by invitation
Quality of life study for HHT patients

This study looks at how hereditary hemorrhagic telangiectasia (HHT) affects your day-to-day life and well-being. By joining, you'll answer questions to help doctors better understand the impact of the condition.

Essen, North Rhine-Westphalia
NCT07623525Recruiting· Phase 1/Phase 2
DIAG723 study for hereditary hemorrhagic telangiectasia

This study tests a new drug called DIAG723 in adults with hereditary hemorrhagic telangiectasia (HHT), a genetic condition that causes abnormal blood vessels and bleeding. Depending on which part of the study you qualify for, the drug may help reduce nosebleeds, improve anemia, or help with lung blood vessel problems caused by HHT.

Camperdown, New South Wales
NCT04469517Recruiting
Study of low-oxygen factors in hereditary bleeding disorder

This study looks at how “low-oxygen” signals may affect people with hereditary hemorrhagic telangiectasia (HHT), a genetic bleeding disorder. It may help researchers understand what drives symptoms and could guide future treatments.

Essen, North Rhine-Westphalia
NCT07743671Not yet recruiting· Phase 3
Engasertib for frequent nosebleeds from HHT

This trial tests an experimental pill, engasertib, to reduce frequent nosebleeds in adults with a rare blood vessel condition called hereditary hemorrhagic telangiectasia (HHT). Participation may help if you have moderate to severe nosebleeds and need iron or blood transfusions.

NCT01761981Recruiting
Registry for patients with hereditary bleeding vessel disease (HHT)

This is a patient registry that collects information about people with hereditary hemorrhagic telangiectasia (HHT). It may help doctors better understand the condition and improve care over time.

Buenos Aires, Buenos Aires

Hear when a new Hereditary Hemorrhagic Telangiectasia trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.